1.ATM and resistance of gliomas to chemotherapy and radiotherapy
Shiming ZHEN ; Lijuan YANG ; Zhixiong LIN
Journal of International Oncology 2011;38(7):506-509
The resistance mechanism of gliomas to chemotherapy and radiotherapy is a complex network of many signaling pathways. It remains unclearhow the pathways interact with each other and how they were regulated. Recent studies have shown that DNA damage checkpoint pathway ( ATM、 ATR、 Chk1、 Chk2、 Rad17、 Radl 、Rad9、Hus1 et al. ) plays an important role in cell proliferation、genomic stability、tumorigenesis and the resistance to chemoradiotherapy of tumors. Inhibiting DNA damage checkpoint can increase tumor sensitivity to chemoradiotherapy and therefore improve the therapeutic effect. We review here the role of ATM in chemoradiotherapy resistance of gliomas and its associated mechanisms.
2.Advances and challenges in the treatment of esophageal cancer.
Shiming HE ; Jian XU ; Xiujun LIU ; Yongsu ZHEN
Acta Pharmaceutica Sinica B 2021;11(11):3379-3392
Esophageal cancer (EC) is one of the most common cancers with high morbidity and mortality rates. EC includes two histological subtypes, namely esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC). ESCC primarily occurs in East Asia, whereas EAC occurs in Western countries. The currently available treatment strategies for EC include surgery, chemotherapy, radiation therapy, molecular targeted therapy, and combinations thereof. However, the prognosis remains poor, and the overall five-year survival rate is very low. Therefore, achieving the goal of effective treatment remains challenging. In this review, we discuss the latest developments in chemotherapy and molecular targeted therapy for EC, and comprehensively analyze the application prospects and existing problems of immunotherapy. Collectively, this review aims to provide a better understanding of the currently available drugs through in-depth analysis, promote the development of new therapeutic agents, and eventually improve the treatment outcomes of patients with EC.